about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Flag­ship start­up Omega takes lead 'epige­nom­ic con­troller' can­di­date clos­er to the clin­ic with new $126M round

5 years ago
Financing

FDA busts Mer­ck­'s Keytru­da in triple-neg­a­tive breast can­cer with a CRL — not un­ex­pect­ed giv­en its dis­as­trous ad­comm

5 years ago
Pharma
FDA+

Glax­o­SmithK­line of­fers fill-fin­ish ca­pac­i­ty to No­vavax for UK sup­ply of Covid-19 vac­cine

5 years ago
Deals
Coronavirus

Look­ing to lift clin­i­cal hold, uniQure con­tends its gene ther­a­py was like­ly not the cause of sin­gle liv­er can­cer case

5 years ago
Cell/Gene Tx
FDA+

No­var­tis push­es back on chair­man's 'i­nac­cu­rate and in­con­sis­ten­t' com­ments un­der­min­ing bribery set­tle­ment

5 years ago
Pharma

No­var­tis walks away from 3rd Zol­gens­ma plant just a year af­ter leas­ing it as it piv­ots re­sources to next-gen pipeline

5 years ago
Pharma
Manufacturing

SEC opens in­quiry in­to Wall Street's SPAC ma­nia — re­port; A Chi­na-based gene ther­a­py play­er now has $80M more in ...

5 years ago
News Briefing

Bris­tol My­ers Squibb out­races the pack to a late-stage tri­al win for its LAG-3/PD-1 an­ti­body com­bo in melanoma

5 years ago
R&D
Pharma

Ex­clu­sive: An in­dus­try con­sor­tium wants to stan­dard­ize cell track­ing for re­gen­er­a­tive meds. Could that avert a ...

5 years ago
Cell/Gene Tx
Manufacturing

Step Phar­ma clos­es $41M round to take en­zyme tar­get­ing lead pro­gram in­to ear­ly-stage tri­al for T cell ma­lig­nan­cies

5 years ago
Financing
Cell/Gene Tx

One of the mas­ter­minds be­hind remde­sivir, Gilead­'s Di­ana Brainard jumps ship to an­tivi­ral T cell play­er AlloVir

5 years ago
People

With at least one gas­tric can­cer ap­proval on the line, Mer­ck­'s Keytru­da scores nod for ear­ly pa­tients in chemo com­bo

5 years ago
Pharma
FDA+

Roche cuts bait on late-stage study of Hunt­ing­ton's med tomin­ersen, an Io­n­is im­port with pri­or safe­ty flags

5 years ago
R&D

Three biotechs set terms in a hunt for $475M-plus; Leap Ther­a­peu­tics earns a tri­al win across DKK1 high ex­press­ing ...

5 years ago
News Briefing

FDA ac­cepts Bris­tol My­er­s' pitch for for­mer MyoKar­dia drug; Clo­vis' Rubra­ca aces ad­vanced ovar­i­an can­cer study

5 years ago
News Briefing

A packed MS mar­ket is about to get busier as J&J's pones­i­mod en­ters the fray

5 years ago
Pharma
FDA+

Mer­ck breathes a sigh of re­lief as Keytru­da-Lenvi­ma com­bo aces con­fir­ma­to­ry study in en­dome­tri­al can­cer

5 years ago
R&D
Pharma

Drum­roll, please: Fu­ji­film Diosynth picks North Car­oli­na as new home for $2B cell-cul­ture su­per­plant

5 years ago
Manufacturing

Re­call re­port: Sagent Phar­ma pulls low blood pres­sure med for loose seal­ing on ster­ile vials

5 years ago
FDA+
Manufacturing

Mer­ck KGaA adds 350 work­ers at French site to build ca­pac­i­ty for 's­in­gle-use' tech for Covid-19 vac­cines, ther­a­pies

5 years ago
Outsourcing
Manufacturing

Pfiz­er lays down its hand on Chi­nese biosims, of­fload­ing its 3-year-old plant to WuXi Bi­o­log­ics as com­pe­ti­tion grows

5 years ago
Manufacturing

Mon­tre­al AI start­up with a tout­ed ad­vi­sor li­cens­es its 'few-shot' plat­form to Re­pare for syn­thet­ic lethal­i­ty ...

5 years ago
Deals
Discovery

Fresh out of the blue­bird bio on­col­o­gy split, Joanne Smith-Far­rell flies the coop to Be Bio and its B cell plat­form

5 years ago
People
Cell/Gene Tx

Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid ...

5 years ago
News Briefing
First page Previous page 13141516171819 Next page Last page
A service from the Financial Times